drugset
drugset / Trial / NCT02801435

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

NCT02801435 ↗

Phase 1 Completed 41 enrolled Betta Pharmaceuticals Co., Ltd. Tigermed Consulting Co., Ltd · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

Timeline

Start
2016-09-17
Primary completion
2017-06-08
Completion
2017-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule 0.5 % Topical
Subject Icotinib Small molecule 1 % Topical
Subject Icotinib Small molecule 2 % Topical
Subject Icotinib Small molecule 4 % Topical

Indications

psoriasis